A1C9KC
Otsuka Holdings Co., Ltd. · LS:A1C9KC
71.50 EUR3.50 +5.15%
Otsuka Holdings Co., Ltd. (LS:A1C9KC) last traded at 71.50 EUR, up 5.15% on the day. Over the past year the stock is up 56.11%. Its 52-week range is 48.00 to 71.50. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open71.50
Day range71.50 – 71.50
52-week range48.00 – 71.50
Volume30
Average volume (10 days)46
Market cap (USD)38.93 B
P/E17.32
EPS (TTM) (USD)4.68
Dividend yield1.44%
Beta (1 year)0.4444
Revenue (TTM) (USD)17.11 B
Employees37.76 K
Performance
+5.15%1 week
+7.52%1 month
+15.32%3 months
+19.17%6 months
+44.74%Year to date
+56.11%1 year
Technical reading
Strongly bullish
Daily summary of what 11 oscillators and 15 moving averages show. See every indicator
Latest headlines
- Otsuka: Strong pharmaceutical growth lifted profit; FY2026 business profit guidance rose to ¥500bnQuartr · 30 Oct 2026
- Otsuka Holdings 9M Results Rise; Lifts FY26 Earnings View, Backs Revenue Forecast; Stock Downdpa-AFX · 30 Oct 2026
- Otsuka Holdings Co., Ltd. - To Retire Treasury Shares Worth 0.84% Of Outstanding Stock On December 11Reuters · 30 Oct 2026
- Otsuka: Strong 9M growth lifted FY2026 profit guidance, while revenue guidance held steadyQuartr · 30 Oct 2026
- Gujarat woos Japanese investors in Tokyo ahead of Vibrant Gujarat summit-2027Business Line · 21 Oct 2026
- Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALSReuters · 22 Sep 2026
- Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary EndpointReuters · 22 Sep 2026
- Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung CancerReuters · 13 Sep 2026
Market data is delayed as each exchange requires (see data coverage). SuperCharting is charting software and gives no investment advice.